Related Experiment Video
Updated: May 22, 2026

Pupillary Response as Assessment of Effective Seizure Induction by Electroconvulsive Therapy
Published on: April 11, 2019
Comparing efficacy of ECT with and without concurrent sodium valproate therapy in manic patients
Leila Jahangard1, Mohammad Haghighi, Gholamreza Bigdelou
1Research Center for Behavioral Disorders and Substance Abuse, Hamadan University of Medical Sciences, Hamadan, Iran.
Objectives:
There is mixed evidence as to the merits of continuing versus discontinuing medication with anticonvulsants before starting electroconvulsive therapy (ECT) in patients with manic episodes. The aim of the present study was therefore to compare, in a controlled double-blind randomized clinical trial, treatment improvements and treatment outcome in patients with current manic episodes while treated with ECT with and without concurrent sodium valproate therapy.
Methods:
A total of 42 inpatients (mean [SD] age, 32.1 [9.6]; 88% men) with bipolar disorders and currently during a manic state took part in the study. They were randomly assigned either to the target group (continuation of sodium valproate administration; minimum, 750 mg/d) or to the control group (discontinuation of sodium valproate administration). All patients underwent bifrontal ECT for at least 6 sessions. Improvements were rated with the Young Mania Rating Scale and the Clinical Global Impression (CGI; CGI-Severity of Illness, and CGI-Improvement).
Results:
Manic episodes as assessed by the Young Mania Rating Scale and CGI improved significantly over time and irrespective of group (target vs control group).
Conclusions:
The pattern of results from this double-blind randomized clinical trial suggests that continuing administration of the anticonvulsant sodium valproate does neither adversely affect nor enhance the efficacy of ECT inpatients with manic episodes.
Related Concept Videos
Electroconvulsive Therapy
Mania and Antimanic Drugs: Overview
Antiepileptic Drugs: Potassium Channel Activators
Ezogabine has gained approval as an adjunctive treatment...
Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
Antiepileptic Drugs: GABAergic Pathway Potentiators
The key GABA pathway potentiators used in epilepsy management are as follows.
Benzodiazepines are a well-known class of drugs used for their...
Antiepileptic Drugs: Sodium Channel Blockers
Sodium channel blockers modulate ion channels, particularly voltage-gated sodium channels. They block only sodium ion movement.
Among the most commonly prescribed antiepileptic drugs are...
